Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02281084
Title Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene Corporation
Indications
Therapies
Age Groups: adult
Covered Countries USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS


No variant requirements are available.